Orly Weinreb

List of Publications by Year
in descending order

71 papers	5,818 citations	109321 35 h-index	85541 71 g-index
72 all docs	72 docs citations	72 times ranked	6069 citing authors

#	ARTICLE	IF	CITATIONS
1	The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia. European Neuropsychopharmacology, 2017, 27, 470-483.	0.7	30
2	The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models. Neuropharmacology, 2017, 123, 359-367.	4.1	30
3	Anti-inflammatory and protective effects of MT-031, a novel multitarget MAO-A and AChE/BuChE inhibitor in scopolamine mouse model and inflammatory cells. Neuropharmacology, 2017, 113, 445-456.	4.1	26
4	A Novel Iron Chelator-Radical Scavenger Ameliorates Motor Dysfunction and Improves Life Span and Mitochondrial Biogenesis in SOD1G93A ALS Mice. Neurotoxicity Research, 2017, 31, 230-244.	2.7	34
5	Iron-Chelating Drugs Enhance Cone Photoreceptor Survival in a Mouse Model of Retinitis Pigmentosa. , 2017, 58, 5287.		20
6	Beneficial Effects of Multitarget Iron Chelator on Central Nervous System and Gastrocnemius Muscle in SOD1G93A Transgenic ALS Mice. Journal of Molecular Neuroscience, 2016, 59, 504-510.	2.3	18
7	Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β‐amyloid in ageing and Alzheimer's disease. British Journal of Pharmacology, 2016, 173, 2080-2094.	5.4	36
8	Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer's disease. Neuropharmacology, 2016, 109, 376-385.	4.1	25
9	Mitochondria: old and new target in brain research. Journal of Neural Transmission, 2016, 123, 81-82.	2.8	2
10	Additive Neuroprotective Effects of the Multifunctional Iron Chelator M30 with Enriched Diet in a Mouse Model of Amyotrophic Lateral Sclerosis. Neurotoxicity Research, 2016, 29, 208-217.	2.7	12
11	Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets. Journal of Neural Transmission, 2016, 123, 125-135.	2.8	31
12	The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 373-383.	2.6	19
13	Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease andÂaging. Neurobiology of Aging, 2015, 36, 1529-1542.	3.1	69
14	Beneficial behavioral, neurochemical and molecular effects of 1-(R)-aminoindan in aged mice. Neuropharmacology, 2015, 99, 264-272.	4.1	10
15	Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice. Neurobiology of Aging, 2015, 36, 2628-2636.	3.1	26
16	Improvement in verbal memory following SSRI augmentation of antipsychotic treatment is associated with changes in the expression of mRNA encoding for the GABA-A receptor and BDNF in PMC of schizophrenic patients. International Clinical Psychopharmacology, 2015, 30, 158-166.	1.7	8
17	Molecular targets of the multifunctional iron‐chelating drug, <scp>M</scp>30, in the brains of mouse models of type 2 diabetes mellitus. British Journal of Pharmacology, 2014, 171, 5636-5649.	5.4	9
18	Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, S132-S136.	2.2	65

#	Article	IF	Citations
19	The Novel Multi-Target Iron Chelator, M30 Modulates HIF-1&#945;-Related Glycolytic Genes and Insulin Signaling Pathway in the Frontal Cortex of APP/PS1 Alzheimer's Disease Mice. Current Alzheimer Research, 2014, 11, 119-127.	1.4	26
20	Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism. Journal of Neural Transmission, 2013, 120, 37-48.	2.8	16
21	Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radical Biology and Medicine, 2013, 62, 52-64.	2.9	163
22	The Role of GABA-A Receptor in the Synergism Between SSRI and Antipsychotic in Schizophrenia; Implications for Antipsychotic Modes of Actions. Current Medicinal Chemistry, 2013, 20, 363-370.	2.4	3
23	Recent Advances in ALS Research: Perspectives for Personalized Clinical Application. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 235-274.	0.6	1
24	Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment. Current Drug Targets, 2012, 13, 483-494.	2.1	123
25	The Novel Multi-Target Iron Chelating-Radical Scavenging Compound M30 Possesses Beneficial Effects on Major Hallmarks of Alzheimer's Disease. Antioxidants and Redox Signaling, 2012, 17, 860-877.	5.4	74
26	Novel Therapeutic Approach for Neurodegenerative Pathologies: Multitarget Iron-Chelating Drugs Regulating Hypoxia-Inducible Factor 1 Signal Transduction Pathway. Neurodegenerative Diseases, 2012, 10, 112-115.	1.4	12
27	Multi-target, Neuroprotective and Neurorestorative M30 Improves Cognitive Impairment and Reduces Alzheimer's-Like Neuropathology and Age-Related Alterations in Mice. Molecular Neurobiology, 2012, 46, 217-220.	4.0	39
28	Targeting dysregulation of brain iron homeostasis in ageing. Nutrition and Aging (Amsterdam,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382	0.3	4
29	Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex. Psychopharmacology, 2012, 220, 763-770.	3.1	3
30	Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice. Mechanisms of Ageing and Development, 2012, 133, 267-274.	4.6	34
31	Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease. International Review of Neurobiology, 2011, 100, 127-149.	2.0	36
32	Understanding the Broad-Spectrum Neuroprotective Action Profile of Green Tea Polyphenols in Aging and Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2011, 25, 187-208.	2.6	129
33	Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim. Journal of Neural Transmission, 2011, 118, 479-492.	2.8	51
34	Does 1-(R)-aminoindan Possess Neuroprotective Properties Against Experimental Parkinson's Disease?. Antioxidants and Redox Signaling, 2011, 14, 767-775.	5.4	9
35	Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application. EPMA Journal, 2010, 1, 343-361.	6.1	21
36	The neuroprotective mechanism of 1â€‹(<i>R</i>)â€‹aminoindan, the major metabolite of the antiâ€‹parkinsonian drug rasagiline. Journal of Neurochemistry, 2010, 112, 1131-1137.	3.9	65

#	ARTICLE	IF	CITATIONS
37	Propargylamine Containing Compounds as Modulators of Proteolytic Cleavage of Amyloid Protein Precursor: Involvement of MAPK and PKC Activation. Journal of Alzheimer's Disease, 2010, 21, 361-371.	2.6	102
38	Neuroprotective Multifunctional Iron Chelators: From Redox-Sensitive Process to Novel Therapeutic Opportunities. Antioxidants and Redox Signaling, 2010, 13, 919-949.	5.4	79
39	Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Progress in Neurobiology, 2010, 92, 330-344.	5.7	150
40	Neuroprotective and neuritogenic activities of novel multimodal ironâ€chelating drugs in motorâ€neuronâ€like NSCâ€34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB Journal, 2009, 23, 3766-3779.	0.5	121
41	Genomic and proteomic study to survey the mechanism of action of the anti-Parkinsonâ€™s disease drug, rasagiline compared with selegiline, in the rat midbrain. Journal of Neural Transmission, 2009, 116, 1457-1472.	2.8	24
42	Molecular mechanisms underlying synergistic effects of SSRIâ€"antipsychotic augmentation in treatment of negative symptoms in schizophrenia. Journal of Neural Transmission, 2009, 116, 1529-1541.	2.8	23
43	The Novel Cholinesteraseâ€"Monoamine Oxidase Inhibitor and Antioxidant, Ladostigil, Confers Neuroprotection in Neuroblastoma Cells and Aged Rats. Journal of Molecular Neuroscience, 2009, 37, 135-145.	2.3	60
44	Neuroprotective molecular mechanisms of (âˆ')-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes and Nutrition, 2009, 4, 283-296.	2.5	208
45	Multifunctional Neuroprotective Derivatives of Rasagiline as Anti-Alzheimer's Disease Drugs. Neurotherapeutics, 2009, 6, 163-174.	4.4	99
46	Physiological and pathological aspects of AÎ² in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic use of iron-chelators. BMC Neuroscience, 2008, 9, S2.	1.9	25
47	The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity. Chemico-Biological Interactions, 2008, 175, 318-326.	4.0	34
48	The application of proteomics for studying the neurorescue activity of the polyphenol (âˆ')-epigallocatechin-3-gallate. Archives of Biochemistry and Biophysics, 2008, 476, 152-160.	3.0	34
49	Simultaneous Manipulation of Multiple Brain Targets by Green Tea Catechins: A Potential Neuroprotective Strategy for Alzheimer and Parkinson Diseases. CNS Neuroscience and Therapeutics, 2008, 14, 352-365.	3.9	204
50	Cell Signaling Pathways and Iron Chelation in the Neurorestorative Activity of Green Tea Polyphenols: Special Reference to Epigallocatechin Gallate (EGCG). Journal of Alzheimer's Disease, 2008, 15, 211-222.	2.6	161
51	The neuroprotective mechanism of action of the multimodal drug ladostigil. Frontiers in Bioscience - Landmark, 2008, Volume, 5131.	3.0	30
52	Novel Multifunctional Anti-Alzheimer Drugs with Various CNS Neurotransmitter Targets and Neuroprotective Moieties. Current Alzheimer Research, 2007, 4, 522-536.	1.4	28
53	Neurorescue Activity, APP Regulation and Amyloid-β Peptide Reduction by Novel Multi-Functional Brain Permeable Iron- Chelating- Antioxidants,M-30 and Green Tea Polyphenol, EGCG. Current Alzheimer Research, 2007, 4, 403-411.	1.4	106
54	Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1356-1362.	4.8	20

#	Article	IF	Citations
55	The Application of Proteomics and Genomics to the Study of Age-Related Neurodegeneration and Neuroprotection. Antioxidants and Redox Signaling, 2007, 9, 169-179.	5.4	44
56	A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidantâ€"iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate. Free Radical Biology and Medicine, 2007, 43, 546-556.	2.9	71
57	Induction of Neurotrophic Factors GDNF and BDNF Associated with the Mechanism of Neurorescue Action of Rasagiline and Ladostigil. Annals of the New York Academy of Sciences, 2007, 1122, 155-168.	3.8	89
58	Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Molecular Nutrition and Food Research, 2006, 50, 229-234.	3.3	248
59	The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex. International Journal of Neuropsychopharmacology, 2006, 9, 287.	2.1	30
60	A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holoâ€APP translation and processing. FASEB Journal, 2006, 20, 2177-2179.	0.5	82
61	Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition. Journal of Neuroscience Research, 2005, 79, 172-179.	2.9	169
62	Regulation of Bclâ€2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB Journal, 2005, 19, 1899-1901.	0.5	158
63	Multifunctional Activities of Green Tea Catechins in Neuroprotection. NeuroSignals, 2005, 14, 46-60.	0.9	320
64	Novel Neuroprotective Mechanism of Action of Rasagiline Is Associated with Its Propargyl Moiety: Interaction of Bcl-2 Family Members with PKC Pathway. Annals of the New York Academy of Sciences, 2005, 1053, 348-355.	3.8	68
65	Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (â€")â€epigallocatechinâ€3â€gallate: implications for neurodegenerative diseases. Journal of Neurochemistry, 2004, 88, 1555-1569.	3.9	337
66	Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. Journal of Nutritional Biochemistry, 2004, 15, 506-516.	4.2	434
67	Neuroprotection via proâ€survival protein kinase C isoforms associated with Bclâ€2 family members. FASEB Journal, 2004, 18, 1471-1473.	0.5	181
68	Gene and Protein Expression Profiles of Antiâ€ and Proâ€apoptotic Actions of Dopamine, Râ€Apomorphine, Green Tea Polyphenol (â€")â€Epigallocatechineâ€3â€gallate, and Melatonin. Annals of the New York Academy of Sciences, 2003, 993, 351-361.	3.8	72
69	Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs. Trends in Pharmacological Sciences, 2003, 24, 184-191.	8.7	71
70	cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB Journal, 2003, 17, 1-26.	0.5	114
71	Green tea polyphenol (â€")â€epigallocatechinâ€3â€gallate prevents Nâ€methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridineâ€induced dopaminergic neurodegeneration. Journal of Neurochemistry, 2001, 78, 1073-1082.	3.9	509